Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the α7 nicotinic acetylcholine receptor: In vitro and in vivo activity

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 12, 2008, Pages 3611-3615

  Acker, Brad A ^a   Jacobsen, E Jon ^a   Rogers, Bruce N ^a   Wishka, Donn G ^a   Reitz, Steven C ^a   Piotrowski, David W ^a   Myers, Jason K ^a   Wolfe, Mark L ^a   Groppi, Vincent E ^a   Thornburgh, Bruce A ^a   Tinholt, Paula M ^a   Walters, Rodney R ^a   Olson, Barbara A ^a   Fitzgerald, Laura ^a   Staton, Brian A ^a   Raub, Thomas J ^a   Krause, Michael ^a   Li, Kai S ^a   Hoffmann, William E ^a   Hajos, Mihaly ^a   Hurst, Raymond S ^a   Walker, Daniel P ^a   more..

^a PFIZER INC   (United States)

Author keywords

7; Azabicyclic; nAChR; Nicotinic; PHA 543613; PHA 709829; Schizophrenia

Indexed keywords

AMPHETAMINE; BENZOTHIAZOLE; BUNGAROTOXIN RECEPTOR; CHLOROBENZAMIDE; FUROPYRIDINE; N [1 AZABICYCLO[3.2.1]OCT 3 YL]FURO[2,3 C]PYRIDINE 5 CARBOXAMIDE; NICOTINIC AGENT; PHA 543613; PHA 709829; PNU 282987; PYRIDINE DERIVATIVE; PYRROLOPYRIMIDINE; THIENOPYRIDINE;

ANIMAL MODEL; ARTICLE; AUDITORY MEMORY; COGNITIVE DEFECT; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT; SCHIZOPHRENIA; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

ANIMALS; AZABICYCLO COMPOUNDS; BENZAMIDES; BICYCLO COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOOD PROTEINS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; MICROSOMES, LIVER; MOLECULAR CONFORMATION; NICOTINIC AGONISTS; PYRIDINES; QUINUCLIDINES; RATS; RECEPTORS, MUSCARINIC; RECEPTORS, NICOTINIC; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 44649098133     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.04.070     Document Type: Article

References (31)

1. Holden C. Science 299 (2003) 333
2. Sawa A., and Snyder S.H. Science 296 (2002) 692
3. Tollefson G.D. J. Clin. Psychiatry 57 (1996) 31
4. For reviews see:. Mazuriv A., Hauser T., and Miller C.H. Curr. Med. Chem. 13 (2006) 1567
5. Jensen A.A., Frolund B., Liljefors T., and Krogsgaard-Larsen P. J. Med. Chem. 48 (2005) 4705
6. Hashimoto K., Koike K., Shimizu E., and Iyo M. Curr. Med. Chem. 5 (2005) 171 and references cited within these papers
7. Freedman R., Hall M., Adler L.E., and Leonard S. Biol. Psychiatry 38 (1995) 22
8. Marutle A., Zhang X., Court J., Piggott M., Johnson M., Perry R., Perry E., and Nordberg A. J. Chem. Neuroanat. 22 (2000) 115
9. Guan Z.Z., Zhang X., Blennow K., and Nordberg A. Neuroreport 10 (1999) 1779
10. Court J., Spurden D., Lloyd S., McKeith I., Ballard C., Cairns N., Kerwin R., Perry R., and Perry E. J. Neurochem. 73 (1999) 1590
11. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., and Byerley W. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 587
12. Olincy A., Harris J.G., Johnson L.L., Pender V., Kongs S., Allensworth A., Ellis J., Zerbe G.O., Leonard S., Stevens K.E., Stevens J.O., Martin L., Adler L.E., Soti F., Kem W.R., and Freedman R. Arch. Gen. Psychiatry 63 (2006) 630
13. Rogers, B. N., Society for Neuroscience Annual Meeting, Satellite Meeting on Nicotinic Acetylcholine Receptors as Therapeutic Targets: Emerging Frontiers in Basic Research & Clinical Science, San Diego, CA, 2007.
14. Bodnar A.L., Cortes-Burgos L.A., Cook K.K., Dinh D.M., Groppi V.E., Hajos M., Higdon N.R., Hoffmann W.E., Hurst R.S., Myers J.K., Rogers B.N., Wall T.M., Wolfe M.L., and Wong E.H. J. Med. Chem. 48 (2005) 905
15. Wishka D.G., Walker D.P., Yates K.M., Reitz S.C., Jia S., Myers J.K., Olson K.L., Jacobsen E.J., Wolfe M.L., Groppi V.E., Hanchar A.J., Thornburgh B.A., Cortes-Burgos L.A., Wong E.H., Staton B.A., Raub T.J., Higdon N.R., Wall T.M., Hurst R.S., Walters R.R., Hoffman W.E., Hajos M., Franklin S., Carey G., Gold L.H., Cook K.K., Sands S.B., Zhao S.X., Soglia J.R., Kalgutkar A.S., Arneric S.P., and Rogers B.N. J. Med. Chem. 49 (2006) 4425
16. Walker D.P., Wishka D.G., Piotrowski D.W., Jia S., Reitz S.C., Yates K.M., Myers J.K., Vetman T.N., Margolis B.J., Jacobsen E.J., Acker B.A., Groppi V.E., Wolfe M.L., Thornburgh B.A., Tinholt P.M., Cortes-Burgos L.A., Walters R.R., Hester M.R., Seest E.P., Dolak L.A., Han F., Olson B.A., Fitzgerald L., Staton B.A., Raub T.J., Hajos M., Hoffmann W.E., Li K.S., Higdon N.R., Wall T.M., Hurst R.S., Wong H.F., and Rogers B.N. Bioorg. Med. Chem. 14 (2006) 8219
17. Walker D.P., Acker B.A., Jacobsen E.J., and Wishka D.G. J. Heterocycl. Chem. 45 (2008) 247
18. 2O: C, 55.50; H, 6.02; N, 12.95. Found: C, 55.76; H, 5.80; N, 12.85.
19. Garberg P., Ball M., Borg N., Cecchelli R., Fenart L., Hurst R.D., Lindmark T., Mabondzo A., Nilsson J.E., Raub T.J., Stanimirovic D., Terasaki T., Oeberg J.-O., and Oesterberg T. Toxicol. In Vitro 19 (2005) 299
20. Seguela P., Wadiche J., Dineley-Miller K., Dani J.A., and Patrick J.W. J. Neurosci. 13 (1993) 596
21. Doses are reported in free base equivalents.
22. Sirota P., Mosheva T., Shabtay H., Giladi N., and Korczyn A.D. Am. J. Psychiatry 157 (2000) 287
23. Compound 3a was screened against a panel of 90 receptors, channels and enzymes at CEREP and found to have no additional activities.
24. Peng X., Katz M., Gerzanich V., Anand R., and Lindstrom J. J. Mol. Pharmacol. 45 (1994) 546
25. Compounds screened in Chan Test, hERG Block Comparitor Screen.
26. The aqueous solubility of compounds 3a and PHA-543613 is greater than 100 mg/mL (HPLC method in pH 7 buffer); thus, solubility should not complicate the results of the hERG assay, which were determined at a concentration of 20 μM.
27. Hajos M. Trends Pharmacol. Sci. 27 (2006) 391
28. Hajos M., Hurst R.S., Hoffmann W.E., Krause M., Wall T.M., Higdon N.R., and Groppi V.E. J. Pharmacol. Exp. Ther. 312 (2005) 1213
29. Hajos, M.; Krause, M.; Hoffmann, W. E.; Hajos-Korcsok, E.; Yu, J. H.; Robinson, D. D.; Wall, T. M.; Higdon, N. R.; Svensson, K. A.; Nichols, N. F.; Walters, R. R.; Groppi, V. E.; Arneric, S. P.; Hurst, R. S. Abstract of Papers, 37th Society for Neuroscience, San Diego, CA, 2007; Abstract 60.9/V17.2007.
30. It is worth noting that since PHA-543613 and PHA-709829 possess essentially equal affinity for the human α7 nAChR (7 nM vs. 9 nM), it is not known whether the improved efficacy of PHA-709829 in the rat auditory gating assay will translate to humans.
31. Krause M., Hoffmann W.E., and Hajós M. Biol. Psychiatry 53 (2003) 244